Neuropeptides in Newborn Blood May Help Objectively Measure Pain in Babies Who Can't Speak

Substance P, neurokinin A, neuropeptide Y, and cortisol levels in newborn blood correlated with pain scale scores, suggesting peptide biomarkers could help objectively measure neonatal pain.

Dionysakopoulou, Christina et al.·Neonatal network : NN·2023·
RPEP-068422023RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Significant decreases in neuropeptide Y (p = 0.02) and neurokinin A (p = 0.03) were observed.

Key Numbers

How They Did This

The study involved 54 full-term neonates and measured biomarker levels alongside two pain assessment scales.

Why This Research Matters

Understanding neonatal pain is crucial for improving care in newborns. Identifying reliable biomarkers can lead to better pain management strategies.

The Bigger Picture

Pain assessment in newborns is one of the most challenging problems in pediatric medicine. Current tools rely on behavioral observations — facial expressions, crying, body movement — which are subjective and can miss pain in sedated or neurologically impaired infants. Peptide biomarkers like substance P and neuropeptide Y offer the possibility of objective, measurable pain indicators. This connects to the broader field of neuropeptide research showing how the brain's pain signaling molecules can be detected in blood.

What This Study Doesn't Tell Us

The study's sample size was limited to 54 neonates, which may affect the generalizability of the findings.

Questions This Raises

  • ?Could a combined peptide biomarker panel plus pain scale score provide more accurate pain assessment than either approach alone?
  • ?Why do male newborns show stronger biomarker-pain correlations, and does this reflect biological sex differences in pain processing?
  • ?Would these peptide biomarkers be useful in premature infants or those receiving sedation, where behavioral pain scales are less reliable?

Trust & Context

Key Stat:
p = 0.02 for NPY change Neuropeptide Y levels significantly decreased in response to painful procedures in full-term newborns
Evidence Grade:
This is a prospective observational study with a modest sample of 54 neonates. While the correlations are statistically significant, the small sample size limits generalizability. The prospective design strengthens the findings compared to retrospective approaches.
Study Age:
Published in 2023, this study represents current research into peptide biomarkers for neonatal pain. The field is still early-stage, and larger validation studies are needed before clinical implementation.
Original Title:
The Role of Substance P, Neurokinin A, Neuropeptide Y, and Cortisol in Assessing Neonatal Pain.
Published In:
Neonatal network : NN, 42(2), 65-71 (2023)
Database ID:
RPEP-06842

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Why is measuring pain in newborns so difficult?

Babies can't verbally report pain, so doctors rely on behavioral signs like crying, facial grimacing, and body movements. These are subjective and can be influenced by many factors. Sedated, premature, or neurologically impaired infants may show few behavioral signs even when experiencing significant pain.

What do substance P and neuropeptide Y have to do with pain?

Substance P is a neuropeptide that transmits pain signals in the nervous system — it's one of the main chemical messengers that tell your brain something hurts. Neuropeptide Y is involved in stress response and pain modulation. Changes in their blood levels reflect what's happening in the pain signaling system.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06842·https://rethinkpeptides.com/research/RPEP-06842

APA

Dionysakopoulou, Christina; Lianou, Loukia; Boutopoulou, Barbara; Giannakopoulou, Margarita; Vlachioti, Efrosini; Koumpagioti, Despoina; Bozas, Evangelos; Matziou, Vasiliki. (2023). The Role of Substance P, Neurokinin A, Neuropeptide Y, and Cortisol in Assessing Neonatal Pain.. Neonatal network : NN, 42(2), 65-71. https://doi.org/10.1891/NN.2022-0006

MLA

Dionysakopoulou, Christina, et al. "The Role of Substance P, Neurokinin A, Neuropeptide Y, and Cortisol in Assessing Neonatal Pain.." Neonatal network : NN, 2023. https://doi.org/10.1891/NN.2022-0006

RethinkPeptides

RethinkPeptides Research Database. "The Role of Substance P, Neurokinin A, Neuropeptide Y, and C..." RPEP-06842. Retrieved from https://rethinkpeptides.com/research/dionysakopoulou-2023-the-role-of-substance

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.